Respiratory Syncytial Virus

RSV poses a serious risk to older adults in long-term care, highlighting the need for effective outbreak management and infection control strategies.

RSV hospitalization in older adults links to increased cardiovascular events, highlighting the need for vigilant monitoring and vaccination strategies.

RSV outbreaks pose significant risks globally, highlighting the urgent need for targeted vaccination and treatment strategies to protect vulnerable populations.

Immunocompromised patients, especially transplant recipients, face heightened RSV risks, leading to severe infections and complications.

Researchers unveil compounds that enhance cell death and boost antiviral responses, offering hope against RSV and other viral infections.

Recent research reveals that RSV and shingles vaccines significantly lower dementia risk, highlighting the potential benefits of AS01 adjuvants in vaccination.

A recent study reveals high RSV antibody levels in older adults, highlighting the importance of vaccination and natural infection for enhanced immunity.

New research highlights the significant health risks of respiratory syncytial virus (RSV) in older adults, emphasizing the need for effective vaccines and public health strategies.

Moderna's mRNA-1345 vaccine gains FDA approval, enhancing protection against RSV for high-risk adults aged 18 to 59 years, following earlier approvals for older populations.

New research analyzes human challenge infection studies to reveal insights on respiratory syncytial virus viral load and symptom dynamics, aiding treatment development.

New research highlights the significant cardiovascular risks associated with RSV, emphasizing the need for vaccination to protect vulnerable populations.

New research highlights the effectiveness and safety of RSV vaccines for older adults, revealing critical insights into vaccination benefits and risks.

Administration during peak vaccine effectiveness provides maximal protective benefit

A recent study highlights the promising immune response and safety of the Arexvy vaccine in lung transplant recipients, crucial for preventing RSV infections.

New research shows adults with RSV-ARI may face significantly higher mortality and health complications, emphasizing the need for targeted vaccination strategies.

New research reveals how aging weakens immune responses to RSV in older adults, increasing severity and hospitalization risks.

The recommendations are not considered to be final until they are published in the Morbidity and Mortality Weekly Report.

The findings suggest a positive impact of RSV vaccination on RSV-associated hospital admission, emphasizing the importance of protection in this population.

A significant portion of unvaccinated individuals were open to future vaccination.

Prioritizing preventive measures for high-risk individuals would effectively address half of RSV hospitalizations.

Although RSV has long been associated with infants and young children, research demonstrates that it is also a significant health risk for adults over the age of 60.

Adults with asthma or COPD face a heightened risk of RSV-related illness.

RSV vaccine acceptance among older adults is significantly influenced by perceived benefits.

RSV infection resulted in higher costs among specific age groups, especially patients aged 70 to 80 years.

Pharmacists play a crucial role in understanding and responding to these developments, ensuring patients remain informed about the latest advancements and potential threats.

RSV poses a significant threat to high-risk adults, but effective vaccines offer strong protection, highlighting the need for increased vaccination rates and education.

Rising seasonal viruses and emerging concerns emphasize the need for public awareness and prevention.

S-337395 demonstrated an 88.4% reduction in viral load and had a statistically significant improvement in clinical symptoms scores.

Antiviral treatments for respiratory viruses such as respiratory syncytial virus (RSV) are crucial, especially with the rise of the "triple-demic."

Approximately 66% of patients received a COVID-19 vaccine in the fall of 2024 and only 26% received a respiratory syncytial virus vaccine.